Resources > Blog > What is Antibody Pharmacokinetics?

What is Antibody Pharmacokinetics?

Biointron 2024-10-16 Read time: 6 mins
pk profiles.jpg
Representative PK profiles for linear and nonlinear clearance at the same doses. DOI:10.1111/cts.12567

Antibody pharmacokinetics (PK) is the study of how the body interacts with antibodies after administration, particularly with absorption, distribution, metabolism, and excretion.1 It is essential in the drug development process, as it allows us to assess the antibody’s therapeutic efficacy and intensity. 

There are several PK features specific to monoclonal antibodies (mAbs). For example, they show biphasic PK profiles in circulation, which means that there is a fast distribution initially, followed by a slower elimination phase. Other mAb‐specific PK characteristics include: confined distribution in vasculature and interstitial spaces due to size and polarity; long half‐lives from FcRn‐mediated recycling; and nonlinear pharmacokinetics from target‐mediated clearance.2

Key Pharmacokinetic Phases

  • Absorption: The process by which the antibody enters systemic circulation. For intravenous (IV) administration, absorption is immediate, while subcutaneous (SC) administration introduces a slower absorption phase as the antibody is gradually released into the bloodstream. 

  • Distribution: Once in circulation, antibodies are distributed throughout the body. However, due to their large size and polarity, they are primarily confined to the vasculature (blood vessels) and interstitial spaces (spaces between tissues and organs). This confined distribution is unique compared to small-molecule drugs, which can easily diffuse into cells and tissues. 

  • Metabolism: Antibodies are primarily metabolized by proteolytic enzymes that break them down into smaller peptides and amino acids. The liver, often a key organ in drug metabolism for small molecules, is less involved in antibody metabolism, as antibodies tend to be cleared through other mechanisms such as cellular uptake. 

  • Excretion: Antibodies are generally excreted through target-mediated clearance mechanisms or catabolism into amino acids, which are then recycled by the body. Unlike small molecules, antibodies are not excreted in urine or feces in significant amounts due to their large size. 

PK Features of mAbs

Biphasic PK Profile: Monoclonal antibodies typically show a biphasic PK profile. After administration, they undergo a rapid distribution phase followed by a slower elimination phase. The initial distribution phase represents the quick movement of the antibody from the blood to the surrounding tissues. The slower elimination phase reflects the prolonged clearance of the antibody from the body, due in part to FcRn (neonatal Fc receptor)-mediated recycling, which extends their half-life. 

FcRn-Mediated Recycling: One of the key features of antibodies, particularly IgG antibodies, is their interaction with the neonatal Fc receptor (FcRn). This receptor binds to antibodies and protects them from lysosomal degradation, recycling them back into circulation. This process significantly extends the half-life of antibodies, often resulting in a half-life of days to weeks, much longer than most small-molecule drugs. 

Target-Mediated Drug Disposition (TMDD): Antibodies, especially those targeting cell surface receptors or circulating proteins, exhibit nonlinear pharmacokinetics due to TMDD. This occurs when the binding of the antibody to its target influences its clearance. At low antibody concentrations, clearance is often faster because many antibody molecules are bound to their target and internalized. As antibody concentrations increase, the target becomes saturated, leading to slower clearance and a nonlinear relationship between dose and clearance rate. 

Factors Influencing Antibody Pharmacokinetics

Several factors can influence the pharmacokinetics of antibodies, including their structure, the target they bind to, and patient-specific variables such as disease state or genetic background:

  • Antibody Structure: The size, glycosylation, and isotype of the antibody can affect its distribution and clearance. For example, glycosylation patterns on the Fc region of the antibody can influence binding to FcRn and, consequently, the recycling process. Additionally, engineered antibodies that lack the Fc region, such as single-chain variable fragments (scFvs), have much shorter half-lives due to their inability to interact with FcRn. 

  • Target Properties: The nature of the antigen (target) plays a significant role in the pharmacokinetics of antibodies. For example, antibodies targeting highly expressed antigens may be cleared more rapidly due to increased target-mediated internalization and degradation. Conversely, antibodies targeting less abundant proteins may have a slower clearance rate. 

  • Patient Factors: Individual variations, including immune system status, disease progression, and organ function, can also impact antibody pharmacokinetics. For instance, patients with compromised immune systems may metabolize antibodies differently, affecting their overall clearance and efficacy.

pk studies.jpg
The alignment of major PK/PD-related studies with the decision points of mAb development in both objectives and recommended studies. DOI:10.1111/cts.12567

Impact of Antibody PK on Therapeutic Efficacy

Antibody pharmacokinetics is directly tied to therapeutic efficacy. Understanding the PK profile of an antibody helps determine the appropriate dosage and frequency of administration to maintain optimal therapeutic levels. For example, antibodies with longer half-lives, due to FcRn recycling, may require less frequent dosing, which can improve patient compliance and reduce treatment costs. PK studies can also help identify potential safety concerns. 

Smaller antibody derivatives, such as Fab fragments, single-chain variable fragments (scFvs), and nanobodies, are becoming increasingly popular in therapeutic and diagnostic applications due to their improved tissue penetration and rapid clearance. However, these derivatives often have shorter half-lives because they lack the Fc region necessary for FcRn-mediated recycling. To address this, strategies such as PEGylation (the attachment of polyethylene glycol chains) are employed to extend the circulation time of these smaller molecules. 

VHH antibodies, derived from camelid antibodies, are an excellent example of small antibody derivatives with distinct PK properties. While their small size enables better tissue penetration, their rapid clearance means they often need to be engineered for longer retention times in the body. 


References: 

  1. Grogan, S., & Preuss, C. (2023, July 30). Pharmacokinetics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557744/

  2. Ovacik, M., & Lin, K. (2018). Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clinical and Translational Science, 11(6), 540-552. https://doi.org/10.1111/cts.12567

Subscribe to our Blog

Recent Blog

Discover Infliximab, the first monoclonal antibody for inflammatory diseases. Explore our catalog of antibody products for in vivo research today.

Nov 05, 2024
Blog

Abinvivo offers a range of antibody products for in vivo research, each designed to meet specific research needs and applications in preclinical studies and antibody development.

Nov 04, 2024
Blog

Complementarity-determining regions (CDRs) are polypeptide sequences within antibodies (Abs) that dictate the specific recognition and binding of antigens. Antibodies are part of the human immune response and are composed of two heavy and two light protein chains. These chains are divided into variable (V) and constant (C) regions, with the V region responsible for binding to unique antigens.

Nov 01, 2024
Blog

Antigens are molecules or molecular structures that are recognized by the immune system, particularly by antibodies, T cells, and B cells. The immune response to an antigen varies depending on the antigen type and the part of the immune system involved. This interaction underpins immunity by helping the body distinguish between self and non-self molecules.

Oct 31, 2024
Blog

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.